About BioCytics


BioCytics, a privately-held biotechnology company located in Huntersville, North Carolina, offers Circulating Tumor Cell isolation, enumeration and analysis services for oncology drug development and research. In addition, BioCytics has an ongoing IRB-approved clinical trial that allows for the collection and study of blood and tissue samples from consenting cancer patients. The research services provided by BioCytics include:

  • CTC Biomarker expression
  • CTC Enumeration
  • Xenograft CTC analysis
  • Collection of blood samples from consenting cancer patients 

 

Mission Statement

BioCytics©’ mission is to research and develop novel cellular therapies for diseases and to accelerate personalized medicine to market.

back to top

 

History

BioCytics© was incorporated in 2005 in Huntersville, North Carolina. It is being incubated by Carolina BioOncology Institute (CBI), a cancer treatment and Phase I drug testing facility. BioCytics© was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also President of CBI.

back to top

 

Alliances

Carolina BioOncology Institute (CBI)?CBI is incubating Biocytics and provides laboratory and office space, as well as laboratory and office equipment and supplies. In addition, CBI opened Biocytics? Clinical Trial #0001.

back to top

 

Facility and Equipment

Biocytics is incubated by Carolina BioOncology Institute, PLLC (CBI www.carolinabiooncology.org ). The 8,000 sq. ft. facility is located at 9801 W. Kincey Avenue, Suite 145, Huntersville, NC 28078.

CBI contains a COLA/CLIA certified laboratory for in-house prognostic and diagnostic testing. In addition to traditional treatment regimens, CBI also provides cancer patients access to novel biologics and therapeutics through its diverse clinical research program.

Because BioCytics is housed within CBI, Biocytics? clinical trials are available to CBI?s oncology patients, thus greatly expediting the efforts to create personalized medicines by enhancing the likelihood of patient accrual on Biocytics? research studies. Additionally, CBI maintains an electronic medical records system that links genomic tumor bank information with clinical research data on IRB approved clinical trials.

Part of CBI?s standard medical care for Stage IV metastatic cancer patients whose tumor is of epithelial origin is to determine circulating tumor cell (CTC) count. This is a pertinent capability for Biocytics as well, providing the means to isolate CTCs from patients in IRB-approved clinical trials, which is the central component in the development of Biocytics? cellular manipulations platforms. There are only two CellTrack Systems (www.veridex.com and www.immunicon.com) located in N.C.: Duke University and CBI. CBI also serves as a centralized reference lab for clinical trial CTC enumeration and performs contracted research for translational laboratory research for CTC immunostaining.

BioCytics equipment includes:

  • CellTracks? Autoprep System for Circulating Tumor Cell Enumeration
  • Roche LightCycler 480 II
  • -20?C and -80?C freezers
  • CO2 incubators with Sensophone alarm system for 24 hour monitoring
  • Biological safety/laminar flow hoods and Nikon inverted microscope for cell culture
  • Clinical Grade Sorvall RC-3BP centrifuge for sample preparation
  • Clean room facility with HEPA filtration and dedicated wet lab space (approximately 2500ft2) for cell processing
  • Lead lined patient exam room for radioisotope-based treatments
  • An associated clinical laboratory that includes full Hematology, Chemistry, Urinalysis, Immunology, and Histology services.
  • Coulter counter for complete blood analysis and Piccolo Chemistry 20 panel
  • Accuri C6 Flow Cytometer
  • CliniMACS Device
  • SpectraMax Plate Reader

back to top